Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E22.97 EPS (ttm)4.45 Insider Own0.40% Shs Outstand1.51B Perf Week0.76%
Market Cap154.51B Forward P/E10.69 EPS next Y9.56 Insider Trans0.40% Shs Float1.49B Perf Month-3.54%
Income7.46B PEG1.00 EPS next Q1.92 Inst Own92.70% Short Float3.22% Perf Quarter14.42%
Sales17.44B P/S8.86 EPS this Y10.40% Inst Trans-0.04% Short Ratio3.32 Perf Half Y40.28%
Book/sh10.50 P/B9.73 EPS next Y18.63% ROA28.60% Target Price118.08 Perf Year49.85%
Cash/sh5.82 P/C17.56 EPS next 5Y23.00% ROE57.70% 52W Range63.50 - 110.64 Perf YTD36.10%
Dividend- P/FCF22.48 EPS past 5Y11.90% ROI18.70% 52W High-7.62% Beta0.77
Dividend %- Quick Ratio2.20 Sales past 5Y16.00% Gross Margin81.20% 52W Low60.96% ATR4.01
Employees6100 Current Ratio2.50 Sales Q/Q136.10% Oper. Margin56.20% RSI (14)48.40 Volatility5.88% 3.52%
OptionableYes Debt/Eq0.59 EPS Q/Q378.30% Profit Margin42.80% Rel Volume0.82 Prev Close100.75
ShortableYes LT Debt/Eq0.49 EarningsOct 28 AMC Payout0.00% Avg Volume14.46M Price102.21
Recom1.70 SMA20-2.01% SMA50-1.40% SMA20018.74% Volume11,869,244 Change1.45%
13-Oct-14Reiterated FBR Capital Outperform $125 → $130
25-Sep-14Reiterated Needham Buy $95 → $120
22-Aug-14Reiterated RBC Capital Mkts Outperform $102 → $115
15-Aug-14Initiated FBR Capital Outperform $125
11-Aug-14Reiterated Argus Buy $90 → $110
28-Jul-14Reiterated Maxim Group Buy $112 → $127
24-Jul-14Reiterated RBC Capital Mkts Outperform $96 → $102
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
20-Oct-14 04:37PM  Will High Price Hurt Gilead Sciences' New Hep-C Drug? at Barrons.com
11:56AM  Senate Lawmaker Eyes Hearing on the Cost of Hepatitis C Treatments at The Wall Street Journal
08:05AM  #PreMarket Primer: Monday, October 20: Fed To Tread Softly At October Meeting Benzinga
17-Oct-14 07:17PM  Lightning Round: Seadrill, Gilead & More at CNBC
05:03PM  Perrigo CEO Constructs "Five Pillars" For Success at Investor's Business Daily
04:24PM  Stocks Up Big Friday, Recover Early Week Losses at Investor's Business Daily
03:30PM  Gilead's Harvoni Receives Notice of Compliance from Canada Zacks
03:29PM  The top 10 best-performing CEOs at Fortune
16-Oct-14 02:44PM  Health Canada issues notice of compliance for Gilead's Harvoni (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C PR Newswire
02:44PM  Health Canada issues notice of compliance for Gilead's Harvoni (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C CNW Group
01:30PM  Health Canada Issues Notice of Compliance for Gileads Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C Business Wire
12:18PM  Buy These Five Beaten-Down Biotech Stocks, Nomura Says at Barrons.com
15-Oct-14 04:20PM  Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Zacks
12:59PM  Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer Zacks
09:35AM  Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths at TheStreet
09:02AM  Is Specialty Pharma Pricing At A Tipping Point? at Forbes
14-Oct-14 06:49PM  Gilead Investor's Business Daily
05:47PM  Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:09PM  Wall Street Ends Mixed; Airlines Soar As Oil Plunges at Investor's Business Daily
04:41PM  US STOCKS- S&P 500, Nasdaq break 3-day slide but Dow dips Reuters
04:23PM  Stocks Close Mixed, Surrendering Some Early Gains at Investor's Business Daily
03:41PM  US STOCKS-Dow, S&P 500 briefly turn negative as energy weighs Reuters
02:55PM  Stocks Retain Gains As Market Finally Gets A Rally at Investor's Business Daily
01:59PM  Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone Benzinga
01:10PM  Drug Analysts Mull End Of 'Double Irish' Loophole at Investor's Business Daily
12:05PM  What's Wrong With Gilead Sciences? at Barrons.com
11:54AM  J&J Earnings Beat; Olysio Chatter Hits Gilead at Investor's Business Daily
10:53AM  Gilead Sciences Falls Amid Worries Over Hep-C Drug Price at TheStreet
12:01AM  [$$] Gilead Planned Stock Sales Hit $35M After Run-Up at Barrons.com
13-Oct-14 04:57PM  Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level Benzinga
04:00PM  Gilead's All-Oral Combo HCV Drug Harvoni Cleared by FDA Zacks
03:54PM  Taking Stock: McCracken, Jeanneret Discuss M&A at Bloomberg
08:40AM  UBS Very Positive on Top Biotech Stocks Ahead of Earnings at 24/7 Wall St.
08:32AM  Big Swings in Biotech Short Interest Benzinga
08:07AM  5 Companies That Could Develop An Enterovirus Treatment Benzinga
10-Oct-14 11:03PM  [$$] Gilead Gets U.S. Approval to Sell New Hepatitis C Drug at The Wall Street Journal
06:54PM  [$$] Gilead's New Hepatitis Drug Gets U.S. Approval at The Wall Street Journal
06:35PM  Most Top Industry Groups Fall Harder Than Market at Investor's Business Daily
05:17PM  New once-a-day pill for hepatitis C wins FDA OK AP
04:46PM  Gilead's Hep C Combo Pill Harvoni Approved, Priced at Investor's Business Daily
04:42PM  Gileads new drug is even pricier than Sovaldi at MarketWatch
04:32PM  U.S. FDA approves Gilead's $94,500 hepatitis C drug Reuters
04:24PM  The week ended like it started, in volatile fashion Yahoo Finance Blogs
03:17PM  Are Pricey Specialty Drugs Really Good Value for the Money? at The Wall Street Journal
02:45PM  Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval at New York Times
02:41PM  Gilead Sciences: FDA Approves All-Oral Hep-C Treatment, Price 'Reasonable and Attractive' at Barrons.com
02:15PM  Gilead Sciences Wins FDA Approval for New Harvoni Hepatitis C Pill at TheStreet
02:03PM  Gilead Sciences' advanced hepatitis C drug approved by FDA at San Jose Mercury News
01:58PM  U.S. FDA approves Gilead's all-oral hepatitis C drug Reuters
01:56PM  Release Confirms Gilead's Approval For Combination Hep C Product Benzinga
01:54PM  U.S. Food and Drug Administration Approves Gileads HarvoniĀ® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C Business Wire
01:52PM  Gilead Wins U.S. Approval for Hepatitis C Combo Pill at Bloomberg
10:49AM  Alger Bets On Healthcare Stocks To Power Through The Volatility at Forbes
10:10AM  Short Interest in Biotech Becomes Company Specific at 24/7 Wall St.
08:38AM  As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles at Forbes
09-Oct-14 06:26PM  Weekly Review List Gets Smaller As Market Slumps at Investor's Business Daily
08-Oct-14 05:10PM  Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo Zacks
01:36PM  Merck, Bristol, Arrowhead Prep Hepatitis Studies at Investor's Business Daily
01:01PM  Gilead Sciences: The Pros and Cons of Sovaldi's Slow Uptake in Europe at Barrons.com
07-Oct-14 07:33PM  Salix, Actavis Among Big Cap Pharmas In Merger Mambo at Investor's Business Daily
01:04PM  Gilead Sciences: Here Comes the Competition at Barrons.com
11:13AM  Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo at Investor's Business Daily
06-Oct-14 12:38PM  Will Biotech Beat This Earnings Season? at Barrons.com
04-Oct-14 08:02AM  Medical Stocks End Week On High Note, Biotechs Lead at Investor's Business Daily
08:02AM  Gilead Among Top IBD 50 Stocks Heading Into Earnings at Investor's Business Daily
01:29AM  [$$] Book Review: Lila by Marilynne Robinson at The Wall Street Journal
03-Oct-14 04:10PM  MannKind Receives $150 Million Upfront Payment from Sanofi Zacks
07:54AM  [$$] Mylan Boosts Full-Year Outlook at The Wall Street Journal
06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy Berkshire Hathaway at TheStreet
02-Oct-14 04:20PM  Lawmakers Probe 'Staggering' Price Hikes for Generic Drugs at The Wall Street Journal
04:20PM  Progenics/Salix's Relistor Label Expanded in the U.S. Zacks
03:52PM  The Great Divergence of 2014 Yahoo Finance Blogs
02:03PM  During times like these, cash is king at MarketWatch
01:03PM  Will Gilead Sciences Score Healthy Gains For Investors? at Investor's Business Daily
01-Oct-14 05:00PM  Why October could be bad for biotech Talking Numbers
02:57PM  Sovaldi pricing raises debate over drug costs at MarketWatch
01:12PM  Machines Rule, Bears Drool Zacks
01:07PM  Why Gilead Sciences (GILD) Stock Is Declining Today at TheStreet
07:42AM  #PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed Benzinga
30-Sep-14 05:43PM  Johnson & Johnson Bets $1.75 Billion On Alios Buy Investor's Business Daily
04:10PM  CorMedix Files IND Application for Neutrolin in the US Zacks
01:23PM  What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences at Barrons.com
12:02PM  J&J Buying Alios, Going Up Against Gilead at Investor's Business Daily
07:39AM  Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% Zacks
07:33AM  France uses tax to put pressure on hepatitis C drug prices Reuters
06:53AM  The Zacks Analyst Blog Highlights: Penn National Gaming, Caesars Entertainment, Wynn Resorts, MGM Resorts International and Gilead Sciences Zacks
06:43AM  Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% Zacks
01:27AM  Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session Zacks
01:27AM  Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session Zacks
29-Sep-14 05:50PM  Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment Zacks
04:55PM  Alimera/pSivida's Iluvien Receives FDA Approval for DME Zacks
04:30PM  Agios to Present Data on AG-120 in November, Shares Rises Zacks
04:20PM  Gilead's HCV Combo Drug Harvoni Secures CHMP Backing Zacks
03:30PM  Gilead Sciences, Inc. Consolidating Gains? Benzinga
08:00AM  Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Zacks
26-Sep-14 07:09PM  Many IBD 50 Stocks Testing Key Support Level at Investor's Business Daily
03:30PM  Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Zacks
02:37PM  Can Gilead Sciences Be A Do-Gooder And Still Do Well? at Investor's Business Daily
08:21AM  Gileads Hepatitis C Combination Wins EU Agency Backing at Bloomberg
07:54AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Zacks
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM